This article is more than 5 years old. Information may no longer be current.

Histogenics names Matthews as chief medical officer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Histogenics Corporation recently announced the appointment of Gloria Matthews, DVM, PhD, DAVCS, as chief medical officer.

Prior to joining the company, Matthews most recently served as senior director and global head of bone and joint research and development at Genzyme. Matthews will now oversee all clinical and medical affairs for Histogenics. According to a company release, she has over 20 years of global research, development and surgical experience in both orthopedics and cartilage repair.

“We are delighted to welcome someone with Dr. Matthews' background and experience to the Histogenics executive team,” Adam Gridley, president and chief executive officer of Histogenics, stated in the release. “With deep relationships both as a clinician and an educator, we're excited to have Dr. Matthews join as at this exciting juncture to lead our ongoing trial[s], and to develop and drive additional future development programs for therapies in the musculoskeletal space.

In addition, her experience with strategic oversight of various United States and global development programs across biologics, drugs and devices will be critical as we further build our pipeline through internal development or strategic alliances.”